Drugs / Oxaloacetate
Oxaloacetate
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02593318 | Oct 2015 → Sep 2018 | Alzheimer disease | Russell Swerdlow | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04290897 | Sep 2021 → Nov 2024 | breast carcinoma in situ | Jonsson Comprehensive Cancer Center | Completed | No outcome recorded |
| Phase 2/31 trial · 1 missed | ||||||
| Phase 2/3 | NCT01741701 | Dec 2012 → Oct 2014 | Parkinson disease | University of Kansas Medical Center | Completed | Missed primary |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT04965987 Comparator | Aug 2025 → Aug 2026 | myasthenia gravis | University of Kansas Medical Center | Withdrawn | No outcome recorded Stop: Business |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Oxaloacetate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04290897 ↗ |
| Known as | Anhydrous Enol-oxaloacetate | “Drug: Anhydrous Enol-oxaloacetate” NCT04290897 ↗ |
| Known as | OAA | “Oxaloacetate (OAA) is a four-carbon molecule involved in many metabolic pathways, including gluconeogenesis, citric acid cycle, glyoxylate cycle, urea cycle, and amino acid metabolism.” NCT04965987 ↗ |
| Route | Oral | “Pills to be taken orally in 500mg dose two times per day” NCT02593318 ↗ |